SHENZHEN, China, Dec. 8, 2025 /PRNewswire/ — Following its strong Kickstarter debut, RoboUP’s new-generation robot mower, the Raccoon 2 SE, has already surpassed 500 backers, reflecting strong demand among small-garden owners. To celebrate, the company is releasing a limited Christmas Surprise Bundle, offering the Raccoon 2 SE with extra blades and boundary ground stakes for a special price of $406.

It’s the kind of practical holiday gift parents truly appreciate. Easy, simple, and designed for stress-free mowing.

• Easy to start, no tech skills needed: No RTK setup, no boundary wire, and even no App required. Users can begin mowing directly by pressing the button on the mower directly.
• Instant, hassle-free mowing: Target Area Mode handles up to 80㎡ with parallel paths, while Spot Cutting Mode delivers a precise 2m×2m squared-spiral pattern (both completely mapping-free).
• Consistent, worry-free results: Auto mapping, scheduled mowing, and auto-return work together to streamline daily lawn care effortlessly.

The Raccoon 2 SE helps busy, dual-income families save time and focus on what matters most, making it a meaningful Christmas gift for those seeking a more relaxed, enjoyable year ahead.

• A tidy yard without extra work: Ride-on-Edge and Edge Mowing reduces and eliminates the need for extra trimming, ensuring clean borders without the manual work.
• Smarter, safer mowing experience: Smart obstacle avoidance helps protect family, pets, and outdoor furniture. The ultra-quiet >56 dB design also ensures the mowing stays non-disruptive.
• Handles your whole yard without supervision: Supports up to three mowing zones, with 36% hill-climbing capability and 80cm narrow-path navigation. This enables smooth, automated coverage for typical home gardens under 500㎡/5,400 sq. ft.

The Raccoon 2 SE Christmas Special Bundle is available until the end of the Kickstarter campaign. Mass production is underway, with first shipments expected in February 2026. The mower comes with a 3-year warranty and 2-year coverage for core components, with repair, replacement, and remote troubleshooting provided as needed. RoboUP service centers are located in Europe and the United States, with the network continually expanding.

This is the final opportunity to secure the Raccoon 2 SE with exclusive holiday perks before prices return to standard tiers. To learn more and claim the Christmas Special while it lasts, join the RoboUP community and visit the campaign page today.

SGS-verified performance results underscore the need for reproducible, third-party testing across the emerging wearable robotics sector

SHENZHEN, China, Dec. 8, 2025 /PRNewswire/ — Hypershell, the originator of the outdoor consumer exoskeleton category, today released the industry’s first Consumer Exoskeleton Standards White Paper, establishing a foundational framework for transparent, reproducible, and scientifically rigorous evaluation of wearable mobility devices. The white paper includes newly published, independently conducted and Société Générale de Surveillance (SGS)-verified test results for the Hypershell X Ultra exoskeleton, marking one of the most comprehensive third-party assessments ever completed for a consumer exoskeleton.

Consumer exoskeletons are emerging as the next frontier in wearable technology, which has expanded in the past decade. As a pioneer in consumer mobility technology, Hypershell is a driving force within the burgeoning exoskeleton category and wearable robotics that is built for performance. Its outdoor exoskeletons significantly reduce physical effort during walking, hiking, uphill climbing, and cycling, to enhance human strength and endurance. As consumer adoption of exoskeletons accelerates, Hypershell is playing a critical role in shaping much more than innovation, by advocating for the creation of universally accepted standards, practices, and safety measures for all personal mobility tech manufacturers.

“For the consumer exoskeleton market to reach its full potential, we need evidence-based measures that clearly define safety, performance, and reliability,” said Kelvin Sun, CEO at Hypershell. “Our white paper is a first step in defining how every exoskeleton—not just ours—should be evaluated, tested, and transparently reported.”

Leading the Call for Industry-Wide Standards

Over the past decade, wearables such as smartwatches, earbuds, and glucose monitors have moved from niche tools to daily essentials. Exoskeletons are following a similar trajectory, but with significantlyhigher responsibility: they directly alter human biomechanics, affect cardiovascular load, and promise to enhance mobility for millions of users.

Yet unlike mature industries such as automotive or medical wearables, the consumer exoskeleton sector lacks shared benchmarks, reproducible test protocols, and transparent reporting frameworks.

Hypershell is calling on manufacturers, policymakers, and standards organizations to collaborate on shared standards that ensure:

• Transparent, science-based evaluation of assistive performance
  
• Consistent safety and reliability expectations across brands
  
• Clear, comparable reporting — enabling consumers to understand real-world benefits

“It’s paramount that our industry galvanizes early on and moves together toward standards that protect consumers, build trust, and accelerate innovation,” Sun continued. “These results demonstrate what is possible when products undergo rigorous, independently verified testing, and we believe this level of transparency should become the norm.”

SGS-Verified Testing Demonstrates Measurable Physical Offloading

The Hypershell X Ultra underwent extensive testing at the Experimental Center of the China Institute of Standardization, with results independently verified by SGS, a global leader in testing, inspection, and certification operating more than 2,500 labs across 115 countries.

Key findings include:

• Lower metabolic cost: VO₂ decreased 20.47% on average during uphill walking with the exoskeleton.
• Reduced heart rate: Average heart rate decreased 22.34%, and maximum heart rate decreased 21.60% during uphill activity.
• Lower muscle activation: EMG measurements showed consistent reductions across major lower-limb muscle groups, indicating meaningful offloading of hip and knee flexor and extensor muscles.
• Multi-modal benefits: Assistive effects extended into cycling, with reduced metabolic and cardiovascular load — benefits historically achieved only through e-bikes.

These improvements show how the exoskeleton makes physical activity easier and more accessible for people who want to keep up with family, enjoy outdoor recreation, or reach fitness goals previously out of reach.

Toward Standardized Consumer Exoskeleton Testing

International bodies such as  American Society for Testing Material International (ASTM), International Organization for Standardization (ISO), and French Association Française de Normalisation (AFNOR) have made progress on exoskeleton standards over the past decade. However, most existing work is focused on medical and industrial applications, leaving a gap in consumer-specific protocols.

Hypershell’s white paper proposes the foundation of such a system—detailing clear, reproducible testing methods, reporting guidelines, and performance metrics, including:

• Clear, technically precise test definitions
• Reproducible protocols for VO₂, EMG, and HR testing
• Uniform reporting formats (analogous to automotive industry metrics)
• Industry-wide transparency regarding firmware, hardware, and testing parameters
• Third-party lab certification and open data sharing

The complete set of findings, testing methods, and validated data is available at: [https://hypershell.tech/pages/exoskeleton-industry-standards]

About Hypershell

Founded in 2021, Hypershell is a wearable robotics company focused on expanding human mobility. Its intelligent exoskeletons adapt in real time to terrain, activity, and intention, making movement lighter and more natural. With SGS-certified performance and more than 20,000 units sold worldwide, Hypershell enhances—not replaces—human ability, shaping a future where wearable robotics become as essential as backpacks for exploration, work, and play.

Media Contact:
FINN Partners
Sophie Soeteber
1 (480) 479-5336
Hypershell@finnpartners.com 

SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ — Leading automotive cybersecurity solutions provider AUTOCRYPT announced on December 8, 2025, the launch of “AutoCrypt PKI-Vehicles,” a new next-generation Public Key Infrastructure (PKI) solution supporting ML-DSA, a post-quantum digital signature algorithm. With its announcement, Autocrypt is among the early leaders to commercialize ML-DSA-enabled PKI that can be applied to automotive systems and OEM-specific environments.

The product launch arrives at a critical time as many global industries prepare for the National Institute of Standards and Technology (NIST) standards for post-quantum cryptography (PQC) and evolving security challenges posed by emerging quantum computing technologies.

Autocrypt’s new product supports ML-DSA, and is among the first to be ready for real-world issuance under this certificate framework across automotive environments. ML-DSA was selected by NIST as part of the FIPS 204 Post-Quantum Digital Signature Standard in 2024, and is considered widely as the global cryptographic baseline. The company is affirming its position as a standard-ready security provider for automotive companies who seek to be future-ready.

“The automotive industry is facing an unprecedented shift in cybersecurity,” said Seokwoo Lee, CEO and Co-Founder of Autocrypt. “Quantum computing is redefining the threat landscape, and the industry must act now to future-proof all vehicles. By bringing this product to automotive manufacturers and suppliers, we are optimizing the process of post-quantum adoption without disrupting existing infrastructure. This launch is the beginning of a new standard for quantum-safe automotive cybersecurity.”

AUTOCRYPT plans on showing its future-proof solutions, including AutoCrypt PKI-Vehicles at the 2026 Consumer Electronic Show (CES) in Las Vegas from January 6-9. Meetings are available by reservation only. To learn more, visit autocrypt.io.  

About Autocrypt

AUTOCRYPT is the leading player in automotive cybersecurity. It specializes in the development and integration of security software and solutions for in-vehicle systems, V2X communications, and Plug&Charge, paving the way towards a secure and reliable transportation ecosystem. Its comprehensive suite of automotive cybersecurity testing solutions includes the award-winning AutoCrypt CSTP, which supports automotive OEMs and suppliers in meeting regulatory standards like ISO/SAE 21434, WP.29 UN R155, and CRA.

• $11B acquisition to deliver end-to-end data platform for businesses to connect, process and govern data for applications and AI agents
• Transaction expected to be accretive to adjusted EBITDA within the first full year, and free cash flow in year two, post close

ARMONK, N.Y. and MOUNTAIN VIEW, Calif., Dec. 8, 2025 /PRNewswire/ — IBM (NYSE: IBM) and Confluent, Inc. (NASDAQ: CFLT), the data streaming pioneer, today announced they have entered into a definitive agreement under which IBM will acquire all of the issued and outstanding common shares of Confluent for $31 per share, representing an enterprise value of $11 billion. Confluent provides a leading open-source enterprise data streaming platform that connects, processes and governs reusable and reliable data and events in real time, foundational for the deployment of AI.

IBM Corporation logo.

IDC estimates that more than one billion new logical applications will emerge by 2028¹, reshaping technology architectures across industries. To fuel meaningful outcomes and drive productivity in operations, these applications, as well as AI agents, need access to connected and trusted data – in real time. IBM and Confluent will enable end-to-end integration of applications, analytics, data systems and AI agents to drive intelligence and resilience in hybrid cloud environments.

“IBM and Confluent together will enable enterprises to deploy generative and agentic AI better and faster by providing trusted communication and data flow between environments, applications and APIs. Data is spread across public and private clouds, datacenters and countless technology providers,” said Arvind Krishna, IBM chairman, president and chief executive officer. “With the acquisition of Confluent, IBM will provide the smart data platform for enterprise IT, purpose-built for AI.”

“Since its founding, Confluent has helped organizations unlock the full potential of their data, driving innovation in an increasingly complex IT landscape. We are extremely proud of the work we’ve done in providing clients with a real-time data streaming platform for the next era of technology, including generative and agentic AI,” said Jay Kreps, CEO & Co-founder, Confluent. “We are excited by the potential to join IBM and to accelerate our strategy with IBM’s go-to-market expertise, global scale and extensive portfolio. I look forward to the future we will build together as Confluent becomes part of IBM.”

The real-time nature of Confluent’s platform is critical for organizations as they leverage data living across all IT environments. Confluent addresses the challenges of today’s technology and data landscape. Confluent excels at preparing data for AI, keeping it clean and connected across systems and applications, eliminating silos inherent in agentic AI. In the last four years alone, Confluent’s total addressable market (TAM) has doubled from $50 billion to $100 billion in 2025². Confluent’s real-time data and event streaming capabilities, combined with IBM’s AI infrastructure software and Automation offerings, will better position the companies to capture this opportunity.

Transaction Rationale

• Strategic Fit: Confluent is a natural fit for IBM, consistent with the company’s hybrid cloud and AI strategy. Data and applications are experiencing dramatic growth – by 2028, global data will more than double, and over one billion new applications will emerge. This exponential growth will be amplified by the continued adoption of AI, increasing demands on IT departments. Organizations around the world turn to IBM to simplify, automate and integrate disparate systems. The addition of Confluent will complement IBM’s existing capabilities in its Data and Automation portfolio. Additionally, the acquisition of Confluent represents further commitment to IBM’s 25-year history of open-source innovation and investment, building on the acquisitions of open-source leaders like Red Hat and HashiCorp.
• Strong Synergy Opportunities: The acquisition of Confluent is expected to drive substantial product synergies across IBM’s portfolio – including AI products and services, Automation, Data and Consulting – and accelerate revenue growth by leveraging IBM’s go-to-market reach. The acquisition is also expected to result in significant operational efficiencies through IBM’s scale and best-in-class productivity actions.
• Attractive Financial Profile: The acquisition of Confluent is expected to accelerate IBM’s growth over time. IBM also anticipates that the transaction will be accretive to adjusted EBITDA within the first full year and free cash flow in year two, post close.

Confluent is headquartered in Mountain View, CA and currently has more than 6,500 clients across major industries – more than 40% of the Fortune 500. The company partners and integrates across the technology industry with leaders like Anthropic, AWS, GCP, Microsoft, Snowflake and more. This is consistent with IBM’s approach to deep industry partnership and working across a broad and open technology ecosystem of application providers, ISVs and hyperscalers.

Confluent is built on Apache Kafka®, an open-source data and event streaming platform for data in motion. Apache Kafka enables fast, reliable and scalable data streaming capabilities for analytics, monitoring and event-driven architectures. Confluent’s platform includes Data Streaming, Connectors, Stream Governance, Stream Processing, Tableflow, Confluent Intelligence and Streaming Agents. The platform has flexible deployment options, including:

• Confluent Cloud: A fully managed deployment of Confluent’s data streaming platform. Its serverless Apache Kafka engine powers the most efficient way to deploy and scale real-time data streams in the cloud.
• Confluent Platform: The self-managed deployment of Confluent’s data streaming platform, powered by a cloud-native, enterprise-grade distribution of Apache Kafka.
• WarpStream: A hybrid Bring Your Own Cloud (BYOC) deployment model with the ease of use of a fully cloud hosted solution, but the cost profile, security and data sovereignty of a self-hosted deployment.
• Confluent Private Cloud: Brings a cloud‑native, managed‑service experience to self‑managed, private environments, applying Confluent Cloud’s Kora innovations to on‑prem and private cloud Kafka workloads.

Transaction Details 
Under the terms of the agreement, IBM will acquire all of the issued and outstanding common shares of Confluent for $31 per share in cash, representing an enterprise value of $11 billion. Confluent will be acquired with available cash on hand.

The board of directors of IBM and the board of directors and independent special committee of Confluent have each approved the transaction. The acquisition is subject to approval by Confluent shareholders, regulatory approvals and other customary closing conditions.

Confluent’s largest shareholders and investors, who collectively hold approximately 62% of the voting power of Confluent’s outstanding common stock, entered into a voting agreement with IBM pursuant to which each has agreed to vote all of their common shares in favor of the transaction and against any alternative transactions.

The transaction is expected to close by the middle of 2026.

Investor Briefing:
An investor briefing is available on the Investor Relations website here: https://www.ibm.com/investor/events/ibm-confluent

About IBM 
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

About Confluent
Confluent is the data streaming platform that is pioneering a fundamentally new category of data infrastructure that sets data in motion. Confluent’s cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations.

Press Contacts
IBM:
Tim Davidson, 914-844-7847
tfdavids@us.ibm.com

Confluent:
Justin Dorff, 510-875-9608
pr@confluent.io

Forward-Looking Statements
Certain statements contained in this communication may be characterized as forward-looking under the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially.

Statements in this communication regarding IBM and Confluent that are forward-looking may include statements regarding: (i) the transaction; (ii) the expected timing of the closing of the transaction; (iii) considerations taken into account in approving and entering into the transaction; (iv) the anticipated benefits to, or impact of, the transaction on IBM’s and Confluent’s businesses; and (v) expectations for IBM and Confluent following the closing of the transaction. There can be no assurance that the transaction will be consummated.

Risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements, in addition to those identified above, include: (i) the possibility that the conditions to the closing of the transaction are not satisfied, including the risk that required approvals from Confluent’s stockholders for the Transaction or required regulatory approvals to consummate the transaction are not obtained, on a timely basis or at all; (ii) the occurrence of any event, change or other circumstance that could give rise to a right to terminate the Transaction, including in circumstances requiring Confluent to pay a termination fee; (iii) possible disruption related to the transaction to IBM’s and Confluent’s current plans, operations and business relationships, including through the loss of customers and employees; (iv) the amount of the costs, fees, expenses and other charges incurred by IBM and Confluent related to the transaction; (v) the risk that IBM’s or Confluent’s stock price may fluctuate during the pendency of the transaction and may decline if the transaction is not completed; (vi) the diversion of IBM and Confluent management’s time and attention from ongoing business operations and opportunities; (vii) the response of competitors and other market participants to the transaction; (viii) potential litigation relating to the transaction; (ix) uncertainty as to timing of completion of the Transaction and the ability of each party to consummate the transaction; and (x) other risks and uncertainties detailed in the periodic reports that IBM and Confluent filed with the SEC, including IBM’s and Confluent’s respective Annual Reports on Form 10-K.  All forward-looking statements in this communication are based on information available to IBM and Confluent as of the date of this communication, and, except as required by law, IBM and Confluent do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Presentation of Information
In an effort to provide investors with additional information, IBM has disclosed in this press release the following non-GAAP information:  free cash flow and adjusted EBITDA; which management believes provides useful information to investors.  Refer to Exhibit 99.2 included in the company’s Form 8-K dated October 22, 2025, for further information regarding the use of these non-GAAP metrics.

Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposed acquisition of Confluent, Inc. (the “Company”) by International Business Machines Corporation (“Parent”) pursuant to the Agreement and Plan of Merger, dated as of December 7, 2025, by and among the Company, Parent and Corvo Merger Sub, Inc. The Company intends to file a preliminary and definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) with respect to a special meeting of stockholders to be held in connection with the proposed acquisition. After filing the definitive proxy statement (the “Proxy Statement”) with the SEC, the Company will mail the Proxy Statement and a proxy card to each stockholder of the Company entitled to vote at the special meeting. The Proxy Statement will contain important information about the proposed transaction and related matters. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, THE COMPANY’S STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC RELATING TO THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION. Investors and stockholders of the Company may obtain a free copy of the preliminary and definitive versions of the proxy statement once filed, as well as other relevant filings containing information about the Company and the proposed acquisition, including materials that are incorporated by reference into the Proxy Statement, without charge, at the SEC’s website (https://www.sec.gov) or from the Company by going to the Company’s Investor Relations Page on its website (https://www.confluent.io).

¹ *Source: IDC, 1 Billion New Logical Applications: More Background, doc #US51953724, April 2024
² Source: Confluent Investor Day Presentation – https://investors.confluent.io/static-files/436f13c5-91cc-4ce7-9c5d-75db958cf9a9

DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ — PT Fapon Bioindustries Indonesia (referred to as “PT Fapon”) and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as “Bio Farma”) officially signed a cooperation agreement at Fapon’s headquarters in Dongguan. The partnership is centered on the local manufacturing, and commercialization of IVD products in Indonesia.

Mrs. Dyah, Chief Executive Officer of Fapon Indonesia Market, and Mr. Dicky, Head of the Business Development Division at Bio Farma, formally executed the agreement on behalf of their respective organizations. This collaboration represents a major advancement in localizing diagnostic technologies and upgrading Indonesia’s healthcare industry.

“We are excited to strengthen our partnership with PT Fapon to localize the production of high-end IVD products in Indonesia,” said Mr. Shadiq Akasya, President Director of Bio Farma. “This collaboration will bolster our national capabilities in medical device manufacturing, thereby enabling broader disease detection coverage across Indonesia.”

Mr. Ben He, President of Fapon Biotech, stated, “PT Fapon is deeply committed to fostering the growth of Indonesia’s healthcare industry through meaningful technology partnerships. We are confident that this technology transfer and localization project will provide Indonesia with cutting-edge diagnostic solutions, and help build a more resilient and sustainable healthcare future.”

PT Fapon is Fapon Group’s first overseas manufacturing base, dedicated to supplying the Indonesian and regional markets with diagnostic products and solutions that meet international standards. Bio Farma, with a legacy spanning over 130 years, is a leading national life science enterprise in Indonesia, boasting extensive expertise in the research, development, production, and distribution of vaccines, biologics, and pharmaceutical products.

This partnership marks a significant milestone in PT Fapon’s strategy to deepen its local roots and empower the autonomous development of Indonesia’s medical industry. Looking ahead, both parties plan to explore further collaborative opportunities in medical innovation and technology transferring, jointly driving progress in healthcare across Indonesia and Southeast Asia.

About PT Fapon Bioindustries Indonesia

PT Fapon Bioindustries Indonesia, located in West Java, is Fapon’s first international manufacturing base. The facility is built and operated in strict compliance with ISO 14644 standards and is dedicated to delivering high-quality in-vitro diagnostic (IVD) products and solutions to the Indonesian market. Leveraging the Fapon Group’s global R&D, manufacturing, and service network, PT Fapon actively introduces advanced diagnostic technologies to support the growth of Indonesia’s local healthcare industry, improve diagnostic accessibility, and contribute to enhancing public health in the country.

About PT Bio Farma (Persero)

PT Bio Farma (Persero) is a world-class, globally competitive life science company that has a role to provide and develop international standard life science products to improve the quality of life. Supported by competence, experience and learning process for more than 130 years, Bio Farma is present as part of the struggle to save and improve the quality of human life. Given the important role in building the nation’s health, Bio Farma’s existence is maintained from time to time.

• Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases.
• These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma.

SURESNES, France, Dec. 8, 2025 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, today announced that Voranigo^® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony held in Stockholm. The Prix Galien Bridges Award recognize outstanding life science innovation across the Nordic countries and their growing bridges with biopharmaceutical communities in key European and Middle Eastern countries, including Austria, Israel, The Netherlands, Portugal, and Spain.

Servier recently announced that Voranigo^® also won the Prix Galien USA Award in the Best Product for Orphan/Rare Diseases category, as well as the Prix Galien Poland Award.

The Prix Galien Award recognizes breakthrough products and outstanding research teams across the pharmaceutical, biotech, medtech, and digital health fields.

“We are truly honored to receive these prestigious distinctions in several countries. It recognizes the scientific progress that Voranigo^® can bring to patients living with glioma across the world”, said Arnaud Lallouette, Executive Vice-President, Global Medical & Patient Affairs. “It rewards Servier’s commitment to innovation and to patients as we continue to advance precision oncology for all who stand to benefit.”

Voranigo^® has been granted marketing authorization for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and who are not in immediate need of radiotherapy or chemotherapy. in the United States, Canada, Australia, Israel, the United Arab Emirates, Saudi Arabia, Switzerland, Brazil, the United Kingdom, in Japan and Europe (27 countries of the European Union as well as Iceland, Liechtenstein and Norway).

Press Contact
presse@servier.com 

About Servier 
Servier is an independent international pharmaceutical company. To find out more please visit the Group website: servier.com
Follow us on social media: LinkedIn, Facebook, X, Instagram 

References  

1. Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma. New England Journal of Medicine, 389(7), 589–601. https://doi.org/10.1056/nejmoa2304194 
2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. PMID: 34185076; PMCID: PMC8328013. 

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — In 2025, Mantle entered a new phase of its evolution. What began as a high-performance Layer-2 rapidly transformed into a full-stack on-chain financial ecosystem, uniting infrastructure, liquidity, institutions, builders, creators, and global communities.

The release of Mantle “2025 RWApped” captures this shift — a year defined by accelerating institutional momentum, rapid RWA expansion, and Mantle’s growing role as the distribution layer connecting traditional finance with on-chain liquidity.

Ecosystem MoMNTum at Scale

In 2025, Mantle reached multiple ecosystem all-time highs, signaling its progression into a more mature, institution-ready network:

• Top-30 ranking on CoinMarketCap & CoinGecko at ATH
• Treasury peaked above $7.9B
• TVL surpassed $2.2B
• Stablecoin supply exceeded $750M
• Global community topped 1M members
• 200+ ecosystem partners and dApps across DeFi, RWAs, infrastructure, and consumer applications

These milestones marked Mantle’s emergence as a credible on-chain venue for real-world finance.

Infrastructure Built for the RWA Era

Two major upgrades in 2025 established Mantle as a high-throughput, institutional-grade settlement layer:

• EigenLayer Integration: As the first and largest L2 to partner with EigenLayer, Mantle unlocked modular security, shared validation, enhanced censorship resistance, and enterprise-grade scalability.
• OP-Succinct via Succinct Labs: Mantle became the first OP Stack L2 to launch as a ZK Validity Rollup, and the largest ZK rollup by TVL, enabling faster settlement, safer execution, and frictionless capital flow between real-world and digital markets.

Together, these upgrades positioned Mantle as an execution and settlement layer for compliant, high-volume RWA activity.

Deep CeFi Integration with Bybit

A core driver of Mantle’s 2025 expansion was its deep, native integration across the Bybit ecosystem, embedding $MNT across spot markets, institutional trading desks, and VIP liquidity programs. This transformed $MNT into a true CeFi-native asset, driving large-scale participation from both retail and institutional traders and forming a powerful distribution bridge between centralized exchange liquidity and on-chain finance.

Global Liquidity Across CeFi and DeFi

As adoption scaled, Mantle’s liquidity footprint expanded worldwide across platforms including Coinbase, Hyperliquid, Moomoo, Backpack, and Coinhako, ensuring seamless access for retail users, professional traders, and institutions deploying capital into Mantle-native applications.

Builders, Creators & Global Community

Ecosystem growth in 2025 was powered by people. Mantle hosted its largest global hackathon to date with 800+ builders, and launched the industry’s first RWA Scholars Program, selecting 6 scholars from 5 countries from over 2,000 global creator submissions.

Mantle also activated its community worldwide through:

• 67 global AMAs
• 25 international events
• 12 developer meetups
• 19 online activations

From ETHDenver and TOKEN2049 to Korea Blockchain Week and CCCC Lisbon, Mantle’s presence became truly global.

Key Strategic Milestones

• 5 Aug 2025 — The Bybit Era Begins: Mantle became the heart of Bybit’s on-chain ecosystem; Helen Liu and Emily Bao joined as Key Advisors.
• 1 Oct 2025 — The RWA Pivot: Mantle went all-in on RWAs with major integrations including Anchorage, Backed/xStocks, Aave, DMZ Finance, Ethena, Agora, and Securitize.
• Oct 2025 — Builders Activated: Launch of Mantle’s First Global Hackathon.
• Nov 2025 — Education Meets RWAs: Debut of the RWA Scholars Program at CCCC Lisbon.

By year-end, Mantle had transitioned from RWA strategy to full ecosystem execution, firmly positioning itself as a distribution layer connecting traditional finance with on-chain liquidity.

Looking Ahead to 2026

With infrastructure hardened, liquidity globalized, and institutional momentum accelerating, Mantle enters 2026 focused on:

• Scaling real-world assets on-chain
• Deepening institutional finance integration
• Expanding global distribution and developer adoption

The MoMNTum continues.

About Mantle

Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with onchain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.

For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel
For media enquiries, please contact: contact@mantle.xyz